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Background: Intratendinous injections may have important effects on the properties of collagen microarchitecture,
morphology, and subsequent mechanical properties of the injected tendon. The purpose of this study was to
examine the effects of intratendinous PRP injections; the injectant retention within tendons, the distribution of
intratendinous injectant, and whether intratendinous injection or needle fenestration alters tendon morphology or
mechanics.
Methods: Design: Controlled Laboratory Study.
Interventions: In the first part of the study, 18 lamb extensor tendons were selected to receive methylene
blue-containing PRP injection (PRP/MB), methylene blue only injection (MB), or needle fenestration. The volume of
retained injectant was measured and injectant distribution and tendon morphology were examined microscopically.
In the second portion of the study, 18 porcine flexor tendons were divided into control, needle fenestration, or
saline injection groups. Young’s Modulus was then determined for each tendon under 0-4% strain.
Main outcome measures: 1) Injectant volume retained; 2) Injectant distribution; 3) Post-injection/fenestration alterations
in morphology, biomechanics.
Results: Intratendinous injectant is retained within the tendon. The difference between PRP and PRP/MB groups was
not significant (p = 0.78). Intratendinous spread of the injectant solution within the tendon occurs primarily in the
proximodistal direction, with very little cross-sectional penetration. Intratendinous injections resulted in microscopic
morphology disruption (e.g., separation and disorganization of both the collagen bundles and cellular distribution).
There were significant differences in Young’s Modulus between control (Ectrl = 2415.48) and injected tendons
(Einj = 1753.45) at 4% strain (p = 0.01). There were no differences in Young’s Modulus between fenestrated and control
tendons.
Conclusions: Intratendinous PRP injections are retained within the tendon, and primarily distributes longitudinally with
minimal cross-sectional spread. Intratendinous injections may alter tendon morphology and mechanics.
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Tendinopathy is a common source of pain and functional
impairment, accounting for 30-50% of sports-related over-
use injuries and affecting large numbers of laborers who
perform repetitive movements (Scott and Ashe 2006;
Forde et al. 2005). Most tendinopathies develop gradually
as a result of repeated physical strain (Kazemi et al. 2010;
Kraushaar and Nirschl 1999). The strenuous and repetitive
nature of recreational and occupational activities can
lead to degenerative tendon alterations, characterized
by collagen fiber disorganization, neovascularity, tendon
thickening, increased cellularity, matrix disorganization,
tenocyte apoptosis, and the clinical manifestations of
pain and dysfunction (Sharma and Maffulli 2006; Jozsa
and Kannus 1997; Cook and Purdam 2009). There is
generally a paucity of inflammatory cells (Khan et al. 1999).
Tendinopathies are often refractory to conservative treat-
ment modalities (e.g. rest, non-steroidal anti-inflammatory
drugs, physical therapy, bracing, corticosteroids) and such
treatments have not been proven to affect healing at the
cellular level (Mishra and Pavelko 2006).
Platelet-rich plasma (PRP) injection therapy has shown
promise as an effective therapy for chronic tendinopathy
(Mishra and Pavelko 2006; Filardo et al. 2010; Barrett
2004; Thanasas et al. 2011; Peerbooms et al. 2010;
Gosens et al. 2011; Mishra et al. 2014). Platelets, which
are small fragments of megakaryocytes that are essential
for normal coagulation, also play a vital role in tissue
healing via their release of platelet-derived growth and
differentiation factors at the site of injury (Lee et al.
2011). PRP injections are proposed to stimulate and aug-
ment regenerative healing of degenerative tissue through
the coordinated action of the PRP growth factors and cy-
tokines (Sampson et al. 2008; Anitua et al. 2006; Anitua
et al. 2005; Molloy et al. 2003). After intratendinous in-
jection, platelets are activated upon exposure to collagen
and local release of thrombin induced by needle fenes-
tration. Upon platelet activation, platelet-derived growth
factors (PDGFs) are released locally where they exert
various responses through local cellular and cytokine
signaling pathways necessary for cell proliferation and
remodeling at the cellular level (Everts et al. 2006).
Recent studies have demonstrated beneficial results
of PRP therapy in chronic tendinopathies, including
those refractory to conventional treatment modalities
(Mishra and Pavelko 2006; Filardo et al. 2010; Barrett
2004; Thanasas et al. 2011; Peerbooms et al. 2010;
Gosens et al. 2011; Mishra et al. 2014). Other research has
demonstrated beneficial effects of saline injections or
simple percutaneous tendon fenestration for tendinopathy
(Housner et al. 2009; McShane et al. 2006; McShane et al.
2008; Testa et al. 2002; Testa et al. 1999; Chan et al. 2008;
Crisp et al. 2008). Despite the emerging evidence for the
efficacy of PRP therapy, it is not known whether thebeneficial effects of PRP injection therapy are a result of the
PRP and its inherent growth factors, or simply due to the
controlled tendon trauma and localized bleeding caused
by the tendon fenestration. Therefore, it is important to
understand whether it is technically feasible for an injectant
to remain within the tendon after intratendinous injection
in order for the hypothesized clinical benefits of the
injectant (e.g., PRP and PDGFs) to be realized.
Similarly, little is known regarding the effects intraten-
dinous injections may have on the properties of collagen
microarchitecture, morphology, and subsequent mech-
anical properties of the injected tendon. Tendons do not
act as rigid structures, but rather demonstrate viscoelastic
properties that allow them to stretch, store, and release
energy transmitted from their associated muscle group
(Maganaris 2002; Alexander 1988; Zajac 1989). Several
studies have demonstrated that tendinopathy alters these
mechanical properties in affected tendons, resulting in
increased cross-sectional area, less tendon stiffness, and
lower Young’s Modulus (Helland et al. 2013; Arya and Kulig
2010). The mechanical alterations due to tendinopathy
result in an inherently weakened tendon structure.
Intratendinous injections or fenestration may have addi-
tional important short-term and long-term effects on
the mechanical properties of tendons. Understanding
these consequences is necessary for optimizing the
tendinopathy treatments while minimizing complications.
The goals of this study are to determine the effects of
intratendinous PRP injections including, (1) the retention
of injectant within the tendon, (2) the distribution of PRP
after intratendinous injection, (3) whether intratendinous
injection or tendon needle fenestration alters tissue
morphology, and (4) whether intratendinous injection




Eighteen fresh frozen lamb extensor carpi radialis tendons
obtained from a local abattoir were dissected, weighed, and
then divided into three subgroups by a single researcher
(MG). PRP was first diluted with .014% methylene blue.
Six tendons were selected to each receive a single 0.25 mL
injection of methylene blue-containing platelet-rich plasma
(PRP-MB), six were prepared to each receive a single
0.25 mL injection of methylene blue alone (MB), and six
served as controls and received only a needlestick without
injection. Platelet-rich plasma was obtained from 20 mL of
whole blood, drawn from the investigator (MG) in lab. The
whole blood was spun in a benchtop centrifuge (Sorvall
Legend, RT+, Thermo Fisher Scientific, Waltham, MA)
for 10 minutes at 312 G, yielding 3.5 mL of un-activated
(e.g., using thrombin or calcium chloride) PRP. The injec-
tions were administered using a 22-gauge, 1.5” needle
Figure 1 Mark-10 force measurement system.
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45-degree angle at the junction of the proximal 1/3 and
middle 1/3 of each dissected tendon. Immediately follow-
ing injection or needlestick, each tendon surface was
gently dabbed dry to remove any extratendinous fluid. The
wet weights of the tendons were obtained before and
immediately after injections using a light balance (Mettler
Toledo, Columbus, OH) with a repeatability of 0.0001 g.
The difference between pre- and post- injection weights
was calculated to determine the volume of injectant
remaining within the tendon. The tendons were then
trimmed to fit into 4.5 cm cassettes, embedded in optimal
cutting temperature (OCT) medium and flash frozen in
liquid nitrogen. Longitudinal sections of the frozen samples
were cut at 10 μm thickness, mounted on Superfrost Plus
(Thermo Fisher Scientific, Waltham, MA) microscope
slides and used for H&E staining. Representative tendon
micrographs of each tendon were collected using a
camera-assisted microscope (Nikon Eclipse microscope,
model E6000, Nikon Instruments, Inc, Mellville, NY with
an Olympus camera, model DP79, Olympus Imaging
America, Inc, Center Valley, PA).
The distribution of the injectant in each sample was
then measured longitudinally (maximum proximodistal
spread) and transversely (maximum diameter of injectant
spread within the tendon) using the H&E micrographs.
The extent of collagen fiber microarchitecture disruption
was also qualitatively assessed.
Tendons embedded in cryostat gel were then sectioned
into 10 μm slices, and mounted onto slides for further ana-
lysis. An experienced tissue histologist (C.C.) then evaluated
injected tendons to measure longitudinal (maximum proxi-
modistal spread) and cross-sectional (maximum diameter
of injectant spread within the tendon) distribution of the
injectant. The same histologist also qualitatively assessed
tendon collagen fiber microarchitecture disruption.
Part two
Eighteen similarly sized porcine flexor digitorum ten-
dons (3rd digit) were excised by a single researcher (NK)
from 18 forelimbs obtained from a local abattoir. Speci-
mens were kept hydrated in physiologic buffered saline
until loading into the mechanical test system. Porcine
flexor tendons, rather than lamb extensor carpi radialis
tendons, were utilized for mechanical testing, since they
were comparable in size (length, weight, circumference)
to the lamb extensor tendons sectioned in part one, and
were conveniently available for testing. Six tendons
served as controls, six received a single needle fenestra-
tion, and six were selected to receive a single 0.25 mL
bolus injection of 0.9% saline within the tendon. The
injections and fenestrations were performed using a
technique identical to part one. Immediately following
the tendon treatments, a Mark-10 ESM301 Test Stand(Mark-10 Corp; Copiague, NY) was used to stretch the
tendons from 0-4% strain (Figure 1). Force was mea-
sured with a MARK-10 Series 5 Force Gauge (Mark-10
Corp; Copiague, NY), and the load and displacement
data were recorded with MESURTM gauge load and
travel analysis software (Mark-10 Corp; Copiague, NY).
From these data stress (Force/Area) and strain ((l-l0)/l0)
were calculated. The Young’s Modulus was calculated as
(stress/strain). The measurements obtained for each ten-
don within each group were then averaged for compara-
tive analysis and paired t-tests were used to examine the
effect of increased strain on Young’s Modulus (E) for
each treatment group.
Results
1) Intratendinous retention of injectant
Pre-injection tendon weight did not significantly differ
among the three groups as determined by one-way
ANOVA (F(2,15) = 0.75, p = 0.49). The post-injection
weight of the tendons in the PRP-MB group increased
by an average of 0.22 ± 0.03 g (Table 1). Based on
the measured density of this fluid (1.40 g/mL), this
correlates to an average of 62.7% of the 0.25 mL
injectant retained per tendon in this group. The
post-injection weights of the MB tendons increased
Table 1 Average volume of injectant retained within tendons of MB only vs. PRP/MB groups
Group Avg. pre-weight (g) Avg. post-weight (g) Avg. increase in weight (g) % Injectant retained P-value
MB Only 2.78 ± 0.26 3.00 ± 0.26 0.23 ± 0.04 54.4 0.78
PRP/MB 2.39 ± 0.21 2.39 ± 0.21 0.22 ± 0.01 62.7
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injectant volume retained, again based on the measured
density of the injected fluid (1.76 g/mL). The average
retention of MB versus PRP-MB was not significantly
different (p = 0.78). As expected, the control needle
fenestration tendons did not have a significant change
in weight.
2) Distribution of injectant
The mean proximodistal penetration of injectant for
the PRP-MB group was 2.91 ± 0.32 cm (Table 2).
This was not significantly different from the MB
group, which had a mean proximodistal penetration
of 2.77 ± 0.40 cm (p = 0.80). The PRP-MB group had a
mean cross-sectional penetration of 0.21 ± 0.06 cm,
significantly less than the average 0.27 ± 0.04 cm seen
in the MB group (p = 0.02).
3) Tissue morphology following injection
Each tendon was examined microscopically after
injection or fenestration for evidence of normal tendon
morphology disruption. Injected tendons (MB and
PRP-MB) consistently demonstrated disruption of
normal tendon morphology compared to control
tendons (needlestick). Characteristic findings of
injected tendons included separation of adjacent
collagen bundles and disorganization of both the
collagen bundles and cellular distribution (Figure 2).
4) Effect of intratendinous injection and fenestration on
tendon mechanical properties
Young’s modulus (E), the slope of the stress–strain
curve, was used as a measure of the tissue
mechanical property in the context of multiple
different levels of tensile strain (0-4%) upon the tissue
(Table 3). The injection group did show a lower
average Young’s Modulus (E = 1753.45 kPa) at 4%
strain compared to control tendons (E = 2415.48 kPa),
demonstrating that injected tendons were significantly
less stiff than controls under the highest level of strain
tested (p = 0.01).ble 2 Average proximodistal and cross-sectional
istribution of injectant in PRP/MB vs. MB only groups
oximodistal Avg. spread (cm) P-value
B only 2.77 ± 0.40 0.80
P/MB 2.91 ± 0.32
oss-sectional
B only 0.27 ± 0.04 0.02
P/MB 0.21 ± 0.06The effect of needle fenestration on the mechanical
properties of tendons was then analyzed, again
measured as Young’s Modulus (E) (Table 4). There
was no significant difference in Young’s Modulus at
any level of strain in the fenestrated group compared
to the control group.Discussion
Intratendinous injections of PRP for tendinopathy are
thought to rely on the intrinsic properties and interplay
between the growth factors contained within plasma and
the platelet alpha granules (Lee et al. 2011). Some of the
important growth factors contained within PRP include
platelet-derived endothelial growth factor, transforming
growth factor-beta, vascular endothelial growth factor,
fibroblast growth factor, epidermal growth factor, and
insulin-like growth factor-1 (Anitua et al. 2004; Lee et al.
2011). Several in vitro and in vivo studies have demon-
strated the ability of PRP to improve healing at the cellu-
lar level (Schnabel et al. 2007; Majewski et al. 2009;
Zhang and Wang 2010; de Mos et al. 2008; Kajikawa
et al. 2008; McCarrel and Fortier 2009). The rapidly
expanding use of PRP clinically, however, has outpaced
the scientific understanding of the precise mechanisms
by which such treatments influence healing. If the hypo-
thetical benefits of PRP stem from its ability to locally
affect cellular healing, then a relevant amount of PRP in-
jectant must remain in the tendon into which it was
injected. It is also important to understand what effects,
if any, these intratendinous injections have on the integ-
rity and biomechanical properties of tissue. To date,
there is limited understanding of the distribution of
intratendinous injections, and, just as importantly, the
resulting histological and biomechanical effects on tis-
sue. Understanding the behavior of injected PRP and its
effects on the tissue have important implications for op-
timizing patient care and outcomes.
We evaluated the intratendinous retention and distri-
bution of PRP into a tendon using ex vivo laboratory
techniques and post-injection histological tissue evalu-
ation. We then examined the biomechanical tissue prop-
erties of fenestrated and injected tendons to determine
whether these treatments have any immediate detrimen-
tal effects on tissue. Our results demonstrate that intra-
tendinous PRP injections are not only feasible, but the
majority of injectant remains within the tendon follow-
ing injection. One study by Wiegerinck and colleagues
looked at the distribution of PRP injected into cadaveric
Figure 2 Morphologic changes in injected tendons versus control. Figures 2a) and 2b) represent the injection process of the PRP/MB and
MB into the lamb tendon. The tendon significantly expands as the solution is injected (2b). H&E images of the 2c) and 2d) fenestrated tendon,
2e) and 2f) MB-injected tendon and 2 g) and 2 h) PRP/MB-injected tendon. Note the methylene blue staining (mb) within the open spaces
between the collagen fibers. Rectangles in 2c), 2e), and 2 g) represent the area captured in images 2d), 2f), and 2 h).
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poorly localized distribution of injectant upon post-
injection dissection and evaluation of the tendon and in-
scribing tissues (Wiegerinck et al. 2011). The results of
our study are similar in that, while the majority of injec-
tant remained within the tendon, there was also amoderate amount of injectant that escaped the tendon
substance, resulting in volume retention of less than
two-thirds of the injectant in all injected tendons in this
trial. A recent retrospective study of pre-and post-
injection ultrasound imaging of tendons injected with
PRP or autologous blood verified that injectant remained
Table 3 Young’s modulus of injected vs. control tendons
at various levels of strain
1% Strain 2% Strain 3% Strain 4% Strain
Average E
Control (kPa)
53.68 444.81 1295.60 2415.48
Average E
Injection (kPa)
63.43 373.55 893.59 1753.45
P-value 0.66 0.56 0.09 0.01
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injected solution was also visualized in tissues adjacent
to the injected area (Loftus et al. 2012). Quantifying the
volume of fluid remaining within the tendon immedi-
ately after the injection however, was not possible using
the aforementioned study methods. Our study agrees
with their findings, but quantifies the amount of solution
remaining within a tendon after injection. Using histo-
logical evaluation, we were also able to quantitatively de-
scribe the characteristics of intratendinous spread of the
fluid and the qualitative effects on tissue morphology
immediately after injection. Loftus and colleagues sug-
gest that the spread of injectant within a tendon pro-
ceeds more distally than expected, aligning with our
findings of predominantly proximodistal spread. They
did not specify, however, the degree of cross-sectional
spread within the tissue, and hypothesized that pepper-
ing techniques may not be necessary given the non-local
spread of injectant within the tissue (Loftus et al. 2012).
Our results suggest that cross sectional spread is min-
imal, which may limit adequate distribution of injectant
within tendon. This is consistent with the results dem-
onstrated by van den Belt and colleagues in a similar
in vitro study of intratendinous injections into horse
flexor tendons (van den Belt et al. 1993). This observa-
tion was particularly evident in PRP-injected tendons in
our study and the significant difference between PRP
and methylene blue only injections limiting cross-
sectional spread may be related to platelet activation and
clotting upon exposure to tendon collagen, resulting in
even further reduced cross-sectional spread across collagen
bundles. This may suggest that larger areas or volumes of
tendinopathy may require a peppering technique to ensure
adequate distribution within the pathologic tissues being
treated, in contrast to the conclusions of Loftus. Multiple
fenestrations associated with a peppering technique mayTable 4 Young’s modulus of fenestrated vs. control
tendons at various levels of strain
1% Strain 2% Strain 3% Strain 4% Strain
Average E
Control (kPa)
53.68 444.81 1295.60 2415.48
Average E
Fenestration (kPa)
60.03 532.03 1333.34 2358.95
P-value 0.82 0.51 0.87 0.76also provide theoretical benefit in creating local bleeding
and exposure to thrombin, a known activator of platelets
and stimulus to an acute healing response. The PRP
utilized in this study was not activated using thrombin or
calcium chloride, and may differ from clinical applications
in which activation of PRP is performed.
The morphology of tendon microarchitecture is notice-
ably altered following intratendinous injection with a fluid
bolus, whereas needle fenestration did not appear to have
a significant effect on visualized tendon morphology. This
may help to explain why intratendinous injections resulted
in alterations of biomechanical properties, specifically de-
creased stiffness (E), with higher strain forces. There was
no significant effect of needle fenestration on the bio-
mechanical properties of tendons compared to controls.
This demonstrates that injected tendons were significantly
less stiff at higher levels of strain than control tendons and
suggests that intratendinous injections may weaken the
injected tendon, at least immediately following injections.
The use of intratendinous injections of PRP is emer-
ging as a therapy for various chronic tendinopathies
(Mishra and Pavelko 2006; Filardo et al. 2010; Barrett
2004; Thanasas et al. 2011; Peerbooms et al. 2010;
Gosens et al. 2011; Mishra et al. 2014). While there is
optimism surrounding PRP therapy, the feasibility and
biomechanical effects of intratendinous injections on the
treated tendon tissue is largely unknown and may have
important implications for determining the optimal
treatment strategy for such tendinopathies. In a letter to
the editor by Knobloch, et al. (Knobloch et al. 2008) in
response to a published study of intratendinous injections
for Achilles tendinopathy (Maxwell et al. 2007), the authors
raised concerns regarding the unknown effect of intratendi-
nous level of collagen distribution on the potential adverse
effects of intratendinous injections. Our study specifically
examined the biomechanical effects, but other deleterious
effects on tendon beyond physical disruption and biomech-
anical detrimental effects are also hypothesized (Abate
et al. 2014). Such proposed effects include risk of pressure-
induced tissue necrosis and focal infections, as well as focal
tendon hypoxia and elevated lactate concentrations in ten-
dons with tendinosis (Knobloch et al. 2008). These effects
should be considered for future study as well.
Further study is warranted at a number of levels to in-
crease our understanding of the effects of intratendinous
injections. While this study demonstrates that a significant
portion of a 0.25 mL injectant can be retained, it is likely
to vary considerably with different injection volumes and
operator dependent techniques. It is also not known
whether the retention and distribution of intratendinous
injections performed in vivo would be altered by factors
such as blood flow and forces placed on the tendons dur-
ing normal motion in the extremity (Wiegerinck et al.
2014). These factors may affect the injectant retention and
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in this study demonstrated visual disruption of normal
morphology and immediately altered mechanical proper-
ties at higher levels of strain, it is not known what effect
these alterations have on long-term function, morphology,
and overall health of tendons in vivo.
A recognized limitation of this study is the fact that
two different species and tendon types were analyzed for
convenience reasons. Although the tendons were simi-
larly sized, and from the forelimb of the animal, it is
plausible that extensor and flexor tendons do not behave
similarly in their response to intratendinous injections
or tendon strain due to inherent differences in their
structural and mechanical properties at baseline. Pollock
and Shadwick’s study on the relationship between mech-
anical properties of various limb flexor and extensor ten-
dons in 18 different quadrupedal mammals with
different body mass did not significantly differ in their
mechanical properties (Pollock and Shadwick 1994).
Therefore, for the purposes of this study, tendon similar-
ities were felt to be sufficient to allow for an initial investi-
gation of the potential effects of intratendinous injections.
Given the relatively small sample size in both parts of
this study and the fact that all measurements were col-
lected at a single point in time immediately after treat-
ment administration, future studies with larger sample
sizes and the ability to measure these variables at mul-
tiple points in time would be very beneficial in better
characterizing the effects of intratendinous injections and
how best to counsel patients receiving this treatment.
Though this study demonstrated alteration of tendon
mechanics in injected tendons at 4% strain, it remains
unknown whether similar alteration would be seen
in vivo or to what significance this type of alteration
may have on likelihood of re-injuries or rupture, which
obviously must be considered when determining timing
for return to activity or sport. Another limitation of this
study is the fact that the effect of intratendinous injec-
tions and fenestration on mechanical properties of the
tendon was only tested to a maximum of 4% strain. In
normal movement and activity, tendons typically experi-
ence strains of less than 4%, predominantly due to
uncrimping of the collagen fibers until reaching roughly
2% strain and then due to actual stretch of the collagen
fibers as strains increase beyond that (Kelc Robi et al.
2013). When a tendon is strained beyond 4%, microfai-
lure of individual fibrils begins to occur and macrofailure
(e.g., rupture) of the tendon typically occurs when it is
stretched to greater than 8-10% its original length (Kelc
Robi et al. 2013; Woo et al. 2000). In porcine tendons,
irreversible damage generally occurs at or above 6.5%
strain (Duenwald-Kuehl et al. 2012). Thus, while our
study suggests that intratendinous injections have the
potential to alter tendon mechanics at strains on theupper limit of those produced with normal activity, fur-
ther research is necessary to investigate whether tendon
mechanics are also altered at higher levels of strain and
whether or not the point of rupture is affected following
these treatments. Similarly, further research is necessary
to determine whether or not the observed alteration of
mechanics is reproducible in an in vivo model and
whether the addition of PRP to the injectant results in
alterations different than those seen with saline injec-
tions. Our results suggest early tendon loading at low
strain is likely acceptable, but it may be prudent to exercise
caution and avoidance of high strain loading of tendons
treated with intratendinous injection in the immediate
period following injection. It is not known how long the
mechanical effects observed in this study may persist.
Conclusions
Intratendinous PRP injections are retained within the
tendon, and primarily distributes longitudinally with
minimal cross-sectional spread. Intratendinous injections
may alter tendon morphology and mechanics.
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